医学通信公司
期刊
会议
图书
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2020, Vol.62 (1592)
摘要:Complete remission of symptoms is the goal of treatment for major depressive disorder; a partial response is associated with an increased risk of relapse. Improvement in symptoms can occur within the first two weeks of treatment with an antidepressant, but it may take 4-8 weeks t...
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2020, Vol.62 (1592)
摘要:Complete remission of symptoms is the goal of treatment for major depressive disorder; a partial response is associated with an increased risk of relapse. Improvement in symptoms can occur within the first two weeks of treatment with an antidepressant, but it may take 4-8 weeks t...
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2020, Vol.62 (1591)
摘要:Icosapent ethyl (Vascepa – Amarin), the ethyl ester of eicosapentaenoic acid (EPA), has been approved by the FDA for use as an adjunct to maximally tolerated statin therapy to reduce the risk of major adverse cardiovascular events in adults with hypertriglyceridemia (≥150 mg...
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2020, Vol.62 (1591)
摘要:Brolucizumab-dbll (Beovu — Novartis), a vascular endothelial growth factor (VEGF) inhibitor, has been approved by the FDA as an intravitreal injection for treatment of neovascular (wet) age-related macular degeneration (AMD). It is the fourth VEGF inhibitor to be approved in...
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2020, Vol.62 (1591)
摘要:The FDA has approved a progestin-only oral contraceptive ("minipill") containing drospirenone (Slynd – Exeltis). All other progestin-only oral contraceptives available in the US contain norethindrone (Camila, and others). Progestin-only oral contraceptives are similar in eff...
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2020, Vol.62 (1591)
摘要:The FDA has approved istradefylline (Nourianz — Kyowa Kirin), an oral adenosine A2A receptor antagonist, for use as an adjunct to carbidopa/levodopa in adults with Parkinson's disease (PD) who experience "off" episodes. Istradefylline is the first adenosine A2A receptor anta...
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2020, Vol.62 (1591)
摘要:Icosapent ethyl (Vascepa – Amarin, the ethyl ester of eicosapentaenoic acid (EPA, has been approved by the FDA for use as an adjunct to maximally tolerated statin therapy to reduce the risk of major adverse cardiovascular events in adults with hypertriglyceridemia (â‰...
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2020, Vol.62 (1591)
摘要:The FDA has approved a progestin-only oral contraceptive ("minipill" containing drospirenone (Slynd – Exeltis. All other progestin-only oral contraceptives available in the US contain norethindrone (Camila, and others. Progestin-only oral contraceptives are similar in effi...
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2020, Vol.62 (1591)
摘要:Brolucizumab-dbll (Beovu — Novartis, a vascular endothelial growth factor (VEGF inhibitor, has been approved by the FDA as an intravitreal injection for treatment of neovascular (wet age-related macular degeneration (AMD. It is the fourth VEGF inhibitor to be approved in t...
作者:Editors from The Medical Letter
来源:[J].The Medical Letter on Drugs and Therapeutics(IF 0.557), 2020, Vol.62 (1591)
摘要:The FDA has approved istradefylline (Nourianz — Kyowa Kirin, an oral adenosine A2A receptor antagonist, for use as an adjunct to carbidopa/levodopa in adults with Parkinson's disease (PD who experience "off" episodes. Istradefylline is the first adenosine A2A receptor anta...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×